Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: ZNF207

Gene summary for ZNF207

Gene summary.

Gene information	Species	Human
	Gene symbol	ZNF207
	Gene ID	7756
	Gene name	zinc finger protein 207
	Gene Alias	BuGZ
	Cytomap	17q11.2
	Gene Type	protein-coding
	GO ID	GO:0000070
	UniProtAcc	O43670

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
7756	ZNF207	GSM4909293	Human	Breast	IDC	2.64e-97	1.07e+00	0.1581
7756	ZNF207	GSM4909294	Human	Breast	IDC	3.97e-07	-2.86e-01	0.2022
7756	ZNF207	GSM4909296	Human	Breast	IDC	4.75e-18	-3.86e-01	0.1524
7756	ZNF207	GSM4909297	Human	Breast	IDC	3.00e-15	-2.38e-01	0.1517
7756	ZNF207	GSM4909298	Human	Breast	IDC	2.12e-02	-1.33e-01	0.1551
7756	ZNF207	GSM4909311	Human	Breast	IDC	9.94e-29	-4.10e-01	0.1534
7756	ZNF207	GSM4909312	Human	Breast	IDC	2.51e-09	-1.43e-01	0.1552
7756	ZNF207	GSM4909319	Human	Breast	IDC	3.00e-36	-4.07e-01	0.1563
7756	ZNF207	GSM4909320	Human	Breast	IDC	7.16e-05	-4.33e-01	0.1575
7756	ZNF207	GSM4909321	Human	Breast	IDC	1.77e-14	-2.41e-01	0.1559
7756	ZNF207	ctrl6	Human	Breast	Precancer	2.88e-02	2.83e-01	-0.0061
7756	ZNF207	brca2	Human	Breast	Precancer	2.96e-02	1.37e-02	-0.024
7756	ZNF207	M1	Human	Breast	IDC	1.61e-15	5.62e-01	0.1577
7756	ZNF207	M2	Human	Breast	IDC	6.37e-05	2.32e-01	0.21
7756	ZNF207	NCCBC14	Human	Breast	DCIS	1.46e-04	-2.94e-01	0.2021
7756	ZNF207	NCCBC3	Human	Breast	DCIS	3.74e-02	-3.00e-02	0.1198
7756	ZNF207	NCCBC5	Human	Breast	DCIS	7.01e-07	-1.85e-01	0.2046
7756	ZNF207	P1	Human	Breast	IDC	1.14e-18	2.55e-01	0.1527
7756	ZNF207	P2	Human	Breast	IDC	1.19e-04	2.91e-01	0.21
7756	ZNF207	DCIS2	Human	Breast	DCIS	1.84e-62	1.66e-01	0.0085

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00508219	Breast	Precancer	protein stabilization	29/1080	191/18723	1.67e-06	6.08e-05	29
GO:00316479	Breast	Precancer	regulation of protein stability	38/1080	298/18723	3.73e-06	1.19e-04	38
GO:003164714	Breast	IDC	regulation of protein stability	50/1434	298/18723	1.14e-07	6.57e-06	50
GO:005082114	Breast	IDC	protein stabilization	35/1434	191/18723	1.12e-06	5.04e-05	35
GO:00512589	Breast	IDC	protein polymerization	38/1434	297/18723	1.26e-03	1.34e-02	38
GO:00330445	Breast	IDC	regulation of chromosome organization	26/1434	187/18723	2.22e-03	2.06e-02	26
GO:00073465	Breast	IDC	regulation of mitotic cell cycle	51/1434	457/18723	4.30e-03	3.35e-02	51
GO:003164724	Breast	DCIS	regulation of protein stability	51/1390	298/18723	1.63e-08	1.15e-06	51
GO:005082124	Breast	DCIS	protein stabilization	36/1390	191/18723	1.82e-07	9.14e-06	36
GO:005125814	Breast	DCIS	protein polymerization	39/1390	297/18723	3.64e-04	5.15e-03	39
GO:000734612	Breast	DCIS	regulation of mitotic cell cycle	52/1390	457/18723	1.38e-03	1.43e-02	52
GO:003304412	Breast	DCIS	regulation of chromosome organization	26/1390	187/18723	1.44e-03	1.47e-02	26
GO:00447724	Breast	DCIS	mitotic cell cycle phase transition	46/1390	424/18723	6.16e-03	4.39e-02	46
GO:0051258	Colorectum	AD	protein polymerization	112/3918	297/18723	1.85e-11	2.27e-09	112
GO:0031647	Colorectum	AD	regulation of protein stability	108/3918	298/18723	6.33e-10	5.08e-08	108
GO:0050821	Colorectum	AD	protein stabilization	73/3918	191/18723	3.02e-08	1.64e-06	73
GO:0010639	Colorectum	AD	negative regulation of organelle organization	114/3918	348/18723	1.41e-07	6.49e-06	114
GO:0033044	Colorectum	AD	regulation of chromosome organization	60/3918	187/18723	2.25e-04	2.94e-03	60
GO:0007051	Colorectum	AD	spindle organization	58/3918	184/18723	4.71e-04	5.20e-03	58
GO:1902850	Colorectum	AD	microtubule cytoskeleton organization involved in mitosis	48/3918	147/18723	5.87e-04	6.21e-03	48

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

ZNF207

SNV

Missense_Mutation

c.157N>T

p.His53Tyr

p.H53Y

O43670

protein_coding

deleterious(0)

probably_damaging(0.969)

TCGA-A8-A094-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

ZNF207

SNV

Missense_Mutation

novel

c.841N>A

p.Val281Ile

p.V281I

O43670

protein_coding

tolerated(0.31)

probably_damaging(0.971)

TCGA-EW-A6SD-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

tch

ZNF207

insertion

Nonsense_Mutation

novel

c.1472_1473insCTAAATACTCGAA

p.Gly492Ter

p.G492*

O43670

protein_coding

TCGA-B6-A0IA-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

ZNF207

SNV

Missense_Mutation

c.715N>G

p.Gln239Glu

p.Q239E

O43670

protein_coding

tolerated(0.23)

benign(0.078)

TCGA-C5-A3HE-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

ZNF207

SNV

Missense_Mutation

c.1300N>T

p.Met434Leu

p.M434L

O43670

protein_coding

deleterious_low_confidence(0.04)

benign(0.138)

TCGA-C5-A7CL-01

Cervix

cervical & endocervical cancer

Female

<65

III/IV

Chemotherapy

cisplatin

ZNF207

SNV

Missense_Mutation

novel

c.679C>T

p.Pro227Ser

p.P227S

O43670

protein_coding

tolerated(0.05)

possibly_damaging(0.457)

TCGA-VS-A8EK-01

Cervix

cervical & endocervical cancer

Female

>=65

I/II

Chemotherapy

cisplatin

ZNF207

SNV

Missense_Mutation

c.849N>G

p.Ser283Arg

p.S283R

O43670

protein_coding

deleterious(0.01)

benign(0.221)

TCGA-A6-2680-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

ZNF207

SNV

Missense_Mutation

novel

c.265N>T

p.Asp89Tyr

p.D89Y

O43670

protein_coding

deleterious(0)

probably_damaging(0.997)

TCGA-AA-3984-01

Colorectum

colon adenocarcinoma

Female

<65

I/II

Unknown

ZNF207

SNV

Missense_Mutation

c.1433G>A

p.Arg478Gln

p.R478Q

O43670

protein_coding

deleterious_low_confidence(0.03)

probably_damaging(0.947)

TCGA-CK-5916-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

ZNF207

SNV

Missense_Mutation

c.974N>A

p.Ser325Asn

p.S325N

O43670

protein_coding

tolerated(0.37)

benign(0)

TCGA-AP-A059-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

Page: 1 2 3 4 5

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1